On 5-6 September 2018 the third multi-stakeholder Paediatric Strategy Forum, jointly organised by ACCELERATE and the European Medicines Agency (EMA) will take place in London. The meeting will focus on checkpoint inhibitors used in combination therapy in children and adolescents.
Immune checkpoint inhibitors have shown impressive success in some adult malignancies, in particular monoclonal antibodies that block the interaction between programmed death ligand 1 (PDL1) on the surface of tumour or antigen-presenting cells, and programmed death 1 (PD-1) on the surface of lymphocytes. Many of these products have now been licensed as first or second line treatments for adult malignancies. The goal of the meeting is to share information, in a pre-competitive setting, to facilitate the development of innovative medicines and ultimately their introduction into the standard-of-care of children with malignancies. Within the Forum, the immunological environment of paediatric malignancies, checkpoint inhibitors in early phase clinical studies in paediatrics, strategies combining checkpoint inhibitors with other products and alternative immunotherapy strategies, will be reviewed.
ACCELERATE is a Horizon 2020 project, supporting the long-term sustainability of large scale Research Infrastructures (RIs) through the development of policies and legal and administrative tools for a more effective management and operation of RIs. The project is coordinated by the Infrastructure CERIC-ERIC (Central European Research Infrastructure Consortium), that operates in the fields of materials, biomaterials and nanotechnology.
More information on the Paediatric Strategy Forum are available at this link.